A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

NCT03833128 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Fatty Acid Oxidation Disorders

Interventions

DRUG: Low Dose REN001
DRUG: High Dose REN001

Sponsor

Reneo Pharma Ltd